1. ALLA AKTIER
  2. NYHETER
  3. ACOUSORT

AcouSort

Nyheter AcouSort Nyheter alla bolag

Leading global pharma company prolongs AcouWash lease for another six months

In October 2024, AcouSort announced a new collaboration with a leading Pharma company. Focus for the initial part of collaboration has been to explore the potential of AcouWash technology in the partnering company’s QC procedures, initially in an R&D setting.

So far, the evaluation of the AcouWash technology has been highly successful, and the partnering company has decided to prolong the evaluation with another six months to finalize the entire evaluation process. The total value of the extension of the collaboration is EUR 11,300.

“This collaboration is very exciting. Not only are we working together with a truly global pharma company, but we are also potentially looking at a completely new field of business for our AcouWash technology. If the finalization of the study goes well, we hope to be able to extend this important collaboration and provide the customer with a solution for long term implementation in their processes,” says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments
Leading global pharma company prolongs AcouWash lease for another six months

Datum 2025-04-01, kl 08:50
Källa MFN
Bifogade filer
Leading global pharma company prolongs AcouWash lease for another six months
Affiliate
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet